Amylyx believes it has found a disease-modifying therapy in AMX0035, as other key readouts approach.
An attempt to abrogate the placebo response does not seem to have gone as planned.
Approval of ALKS 3831 looks likely after Friday’s positive panel vote, but sales might disappoint.
Our final look at upcoming catalysts sees data expected from Replimune, TCR2 Therapeutics, Anavex and more.
Oncology dominates upcoming catalysts, while results elsewhere are expected in Alzheimer’s, psoriasis and diabetes.
The next big approach in Alzheimer’s has been dealt a blow, and there are plenty more tau-targeting contenders.
Marinus celebrates pivotal trial success with ganaxolone, but a quick approval could depend on lenient regulators.
Licensing deal could enable bundling of antipsychotics with management technology.